|
|
||||||||
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305
The unique Ag-presenting capabilities of dendritic cells (DCs) make them attractive vehicles for the delivery of therapeutic cancer vaccines. While tumor Ag-pulsed DC vaccination has shown promising results in a variety of murine tumor models and early clinical trials, the optimal form of tumor Ag for use in DC pulsing has not been determined. We have studied DC vaccination using alternative forms of a soluble protein tumor Ag, the tumor-specific Ig idiotype (Id) expressed by a murine B cell lymphoma. Vaccination of mice with Id-pulsed DCs was able to induce anti-Id Abs only when the Id was modified to constitute a hapten-carrier system. DCs pulsed with Id proteins modified to include foreign constant regions, foreign constant regions plus GM-CSF, or linkage to keyhole limpet hemocyanin (KLH) carrier protein were increasingly potent in their ability to elicit anti-Id Abs. Vaccination with Id-KLH-pulsed DCs induced tumor-protective immunity superior to that obtained with Id-KLH plus a chemical adjuvant, and protection was not dependent upon effector T cells. Rather, protection was associated with the induction of high titers of anti-Id Abs of the IgG2a subclass, characteristic of a Th1 response. These findings have implications for the design of therapeutic Ag-pulsed DC vaccines for cancer immunotherapy in humans.
This article has been cited by other articles:
![]() |
S. Cohen, J. Haimovich, and N. Hollander Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma J. Immunol., February 1, 2009; 182(3): 1667 - 1673. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas J. Immunol., September 15, 2008; 181(6): 4131 - 4140. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Franki, K. K. Steward, D. J. Betting, K. Kafi, R. E. Yamada, and J. M. Timmerman Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo Blood, February 1, 2008; 111(3): 1504 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Fredriksen and B. Bogen Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences Blood, September 15, 2007; 110(6): 1797 - 1805. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kanter, J. Yang, A. Voloshin, S. Levy, J. R. Swartz, and R. Levy Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines Blood, April 15, 2007; 109(8): 3393 - 3399. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Song and R. Levy Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Naive Dendritic Cells Cancer Res., July 1, 2005; 65(13): 5958 - 5964. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Torres, R. May, M. D. Scharff, and A. Casadevall Variable-Region-Identical Antibodies Differing in Isotype Demonstrate Differences in Fine Specificity and Idiotype J. Immunol., February 15, 2005; 174(4): 2132 - 2142. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-K. Weng, D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype J. Clin. Oncol., December 1, 2004; 22(23): 4717 - 4724. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. D. Davis, W. Chen, H. Jackson, P. Parente, M. Shackleton, W. Hopkins, Q. Chen, N. Dimopoulos, T. Luke, R. Murphy, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans PNAS, July 20, 2004; 101(29): 10697 - 10702. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. May, D. O. Beenhouwer, and M. D. Scharff Antibodies to Keyhole Limpet Hemocyanin Cross-React with an Epitope on the Polysaccharide Capsule of Cryptococcus neoformans and Other Carbohydrates: Implications for Vaccine Development J. Immunol., November 1, 2003; 171(9): 4905 - 4912. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Haicheur, F. Benchetrit, M. Amessou, C. Leclerc, T. Falguieres, C. Fayolle, E. Bismuth, W. H. Fridman, L. Johannes, and E. Tartour The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization Int. Immunol., October 1, 2003; 15(10): 1161 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gilliet, M. Kleinhans, E. Lantelme, D. Schadendorf, G. Burg, and F. O. Nestle Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen Blood, July 1, 2003; 102(1): 36 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. Chen, Y.-P. Lee, Y.-F. Chung, Y.-C. Shih, J.-P. Tsai, M.-H. Tao, and C.-C. Ting Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy Int. Immunol., March 1, 2003; 15(3): 427 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gatza and C. Y. Okada Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma J. Immunol., November 1, 2002; 169(9): 5227 - 5235. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Chang, B. G. Redman, J. R. Whitfield, B. J. Nickoloff, T. M. Braun, P. P. Lee, J. D. Geiger, and J. J. Mule A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1021 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Timmerman, D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood, March 1, 2002; 99(5): 1517 - 1526. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression Cancer Res., December 1, 2001; 61(23): 8513 - 8519. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines Cancer Res., September 1, 2001; 61(17): 6445 - 6450. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shimizu, E. K. Thomas, M. Giedlin, and J. J. Mulé Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein Cancer Res., March 1, 2001; 61(6): 2618 - 2624. [Abstract] [Full Text] |
||||
![]() |
J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas Blood, March 1, 2001; 97(5): 1370 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Candido, K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents Cancer Res., January 1, 2001; 61(1): 228 - 236. [Abstract] [Full Text] |
||||
![]() |
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman Immunotherapy of Non-Hodgkin's Lymphomas Hematology, January 1, 2001; 2001(1): 221 - 240. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |